Endotracheal DNase for atelectasis in ventilated neonates

Area of Science:

• Neonatal intensive care
• Pulmonary medicine
• Respiratory therapy

Background:

• Atelectasis and lung collapse are common challenges in ventilated neonates.
• Recombinant human DNase (rhDNase) is used to liquefy sputum in conditions like cystic fibrosis, asthma, and bronchiectasis.
• Its potential in neonatal respiratory failure is unexplored.

Observation:

• This study explored rhDNase use in four ventilated neonates with severe respiratory failure and atelectasis.
• Three patients demonstrated clinical improvement after rhDNase administration.
• One patient was later found to have an undiagnosed lung anomaly.

Findings:

• rhDNase administration showed potential clinical benefit in a subgroup of ventilated neonates with severe respiratory failure.
• The therapy appeared to aid in managing atelectasis in this critical patient population.
• These preliminary results suggest a possible role for rhDNase in neonatal respiratory distress.

Implications:

• rhDNase may offer a novel therapeutic option for ventilated neonates suffering from severe respiratory failure and atelectasis.
• Further randomized controlled trials are warranted to validate these findings and establish efficacy.
• This research opens avenues for exploring mucolytic agents in neonatal respiratory care.